It has been one hot summer, especially here in the Dallas-Fort Worth, Texas, area. We saw a record-breaking streak of consecutive days over 100 °F and without rain.
With the summer months sweltering on, the editors and contributors of Contemporary OB/GYN® have been hard at work carefully crafting a great issue that touches upon a variety of subjects within obstetrics and gynecology.
There are several excellent must-read articles this month:
The cover story is an article by Melissa M. Mauskar, MD; Hunter J. Pyle, BBA; and Audrey K. Rutherford, MD, on vulvovaginal dermatology essentials needed every day to accurately identify various vulvar conditions and determine the appropriate treatment. the authors also provide information on how to best approach patients with vulvovaginal concerns in the clinic.
The Contraception section article, written by Danielle M. Alm, PharmD, BCPs, BCPPs; Reina Puri; and Christine Payne, takes a deep dive into the various contraceptives on the market and describes some best practices for discussing birth control with adolescent patients.
The Practice Matters column by Brian K. Iriye, MD; and James D. Keller, MD, provides thoughtful and informative tips on how to make meetings both effective and efficient.
The Life Transitions section explains the latest phase 3 data for fezolinetant (Astellas Pharma) to treat moderate to severe vasomotor symptoms associated with menopause. The data were presented at the American College of Obstetricians and Gynecologists' Annual Clinical and Scientific Meeting in May 2022 in san Diego, California.
Finally, the Well Woman section features an article by Bertie Geng, MD; and Alla Vash-Margita, MD, about cervical cancer screening guidelines in adolescents. And although average-risk adolescents don’t need Papanicolaou tests, this article gives an update on special populations of adolescent patients who do.
So, as you sit back, relax, and read this August issue of Contemporary OB/GYN® (I hope by a pool or in the shade), please let me know whether there are any topics you would be interested in reading about. Email me at cspong@mjhlifesciences.com.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More